Anthem Biosciences: Should You Buy, Hold, or Sell Right Now?

Anthem Biosciences share price is trading close to its 52-week high of Rs 973.50, with Anthem Biosciences share price around Rs 934 on the NSE, more than 61 percent above its 52-week low of Rs 579.15. With a softer Q1 FY27 following a very strong FY26, investors are asking whether this CRDMO company is a stock to buy near its highs, a hold, or a sell given the rich valuation.

This Anthem Biosciences stock analysis walks through the Q1 FY27 numbers, the strong FY26 backdrop, valuation against the pharmaceutical services sector, shareholding pattern and the technical setup, using figures sourced from company disclosures and public filings.

Click Here – Get Free Investment Predictions

About Anthem Biosciences

Before deciding on Anthem Biosciences share price, it helps to understand the underlying business. Anthem Biosciences Ltd. is a contract research, development and manufacturing organisation (CRDMO), serving pharmaceutical and biotechnology customers with drug discovery, development and manufacturing services spanning small molecules, biologics and specialty ingredients.

As a CRDMO, Anthem Biosciences' quarterly results can show variability tied to project timing and customer order patterns, and the company's Q1 FY27 results show a decline in both revenue and profit following a very strong full FY26 year.

Anthem Biosciences Share Price Today: Key Levels

The table below summarises where Anthem Biosciences share price stands right now against its recent trading range and market value.

Metric	Value
Anthem Biosciences CMP (NSE)	Rs 933.50
Anthem Biosciences CMP (BSE)	Rs 934.00
52-Week High	Rs 973.50
52-Week Low	Rs 579.15
Market Capitalisation	Approximately Rs 52,599 crore
Dividend Yield	0.21%

Anthem Biosciences share price is trading close to its 52-week high, having risen substantially from its 52-week low, even as the most recent quarter's revenue and profit both declined.

Check the Univest Screener for Live Stock Data

Anthem Biosciences Financial Performance

The Anthem Biosciences share price trend is closely tied to how these numbers evolve each quarter. Anthem Biosciences reported Q1 FY27 (June 2026 quarter) revenue of Rs 443.11 crore, down 21.3 percent year on year from Rs 563.02 crore, and down sequentially from Rs 662.15 crore in the March 2026 quarter, with net profit falling 11.7 percent year on year to Rs 119.94 crore from Rs 135.79 crore.

For the full year FY26, the company reported revenue of Rs 2,280.12 crore, up 18.1 percent year on year, with net profit of Rs 591.79 crore, up a strong 31.2 percent from Rs 451.26 crore in FY25, confirming the full year as a whole delivered very strong growth despite the recent quarter's softer showing.

Period	Revenue	Net Profit	Comment
Q1 FY27 (Jun 2026)	Rs 443.11 crore	Rs 119.94 crore	Revenue -21.3%, profit -11.7% YoY
FY26 (full year)	Rs 2,280.12 crore	Rs 591.79 crore	+18.1% revenue, +31.2% profit YoY

Valuation Check: Is Anthem Biosciences Share Price Expensive?

Any view on Anthem Biosciences share price should start from these valuation multiples. Anthem Biosciences share price currently reflects a price to earnings ratio of about 91.29 times trailing earnings, a very significant premium to the broader pharmaceutical services sector average of roughly 37.7 times. The price to book ratio stands near 17.3 times, supported by a strong 19.45 percent return on equity.

Debt to equity of 0.02 is very low. Given the softer Q1 FY27 results following the very strong FY26 year, this very rich valuation leaves limited room for disappointment and requires the CRDMO project pipeline to reaccelerate to justify the current premium.

Technical Signals: What the Chart Shows

Price action here often foreshadows the next move in Anthem Biosciences share price. Anthem Biosciences share price is currently positioned close to its 52-week high of Rs 973.50, more than 61 percent above its 52-week low of Rs 579.15, reflecting a strong overall run over the past year despite the recent quarterly softness. A stock trading this close to its high, even amid a softer quarter, typically signals the market's continued confidence in the company's longer-term CRDMO growth story.

Trading volumes remain heavy, so investors should track Anthem Biosciences share price alongside continued project pipeline and order momentum in coming quarters, rather than reacting to the recent quarter's decline alone at these technical levels.

Download the Univest iOS App or Univest Android App to track Anthem Biosciences' live price and technical levels.

Shareholding Pattern

Shifts here can influence Anthem Biosciences share price more than headline news on some sessions. Anthem Biosciences is a promoter-led CRDMO with a very low leverage balance sheet. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company's latest exchange filing.

Why Investors Are Watching Anthem Biosciences

• Very strong FY26 annual growth: Full-year profit grew 31.2 percent year on year, showing the underlying business delivered very strong growth over the full year despite the recent quarter's softness.
• Diversified CRDMO service offering: Spanning small molecules, biologics and specialty ingredients provides diversification across multiple pharmaceutical service categories.
• Very low financial leverage: A debt to equity ratio of just 0.02 gives the company significant financial flexibility.
• Strong stock performance over the past year: The stock has risen more than 61 percent from its 52-week low, reflecting sustained investor confidence.

Risks and Factors to Watch

• Softer Q1 FY27 results: Revenue fell 21.3 percent and profit fell 11.7 percent year on year in the most recent quarter, a real deterioration that investors should not overlook.
• Very rich valuation: A 91.29x PE, a very significant premium to the pharmaceutical services sector, leaves essentially no room for disappointment if the project pipeline does not reaccelerate.
• CRDMO project timing variability: As a contract research and manufacturing organisation, quarterly results can show significant variability tied to project timing and customer order patterns.
• Competitive CRDMO market: Anthem Biosciences competes against other domestic and global CRDMO players in a competitive pharmaceutical services market.

Anthem Biosciences Share Price Target: What the Data Suggests

Until then, Anthem Biosciences share price remains best tracked through live, verified data rather than a single fixed number. Anthem Biosciences does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. What the data shows is a company with a very strong FY26 track record working through a softer recent quarter, trading at a very rich premium to the sector.

Investors who want live, updated research can check the Univest Screener, and should consult a SEBI-registered investment adviser given the very rich valuation involved.

Anthem Biosciences: Should You Buy, Hold, or Sell Right Now?

This is the core question behind Anthem Biosciences share price right now. The Anthem Biosciences buy or sell decision depends on whether the Q1 FY27 softness proves temporary.

The case for buying: Investors who believe in Anthem Biosciences' diversified CRDMO business and its very strong FY26 track record may find the current level, near its 52-week high, justified despite the recent quarter's softness.

The case for holding: Existing shareholders who have benefited from the stock's strong run may prefer to stay invested while monitoring the project pipeline.

The case for waiting: Valuation-sensitive investors uncomfortable with a 91.29x PE amid the recent quarterly decline may prefer to wait for a larger valuation cushion or clearer confirmation of reacceleration.

Historically, diversified CRDMO companies with strong execution have rewarded patient investors, but very rich valuations can compress sharply if growth slows, so weigh this against your own risk tolerance and consult a SEBI-registered investment adviser if unsure.

Conclusion

Anthem Biosciences share price reflects a diversified CRDMO company with a very strong FY26 track record, even as Q1 FY27 revenue and profit both declined, trading close to its 52-week high at a very rich premium to the pharmaceutical services sector. This article is for informational purposes and not a personalised investment recommendation.

Q1. Is Anthem Biosciences a good stock to buy right now?

Ans. Anthem Biosciences' Q1 FY27 revenue and profit both declined year on year, following a very strong full FY26 in which profit grew 31.2 percent. The stock trades at a very rich 91.29 times earnings, so it suits growth investors who believe strongly in the company's CRDMO business despite the recent softness.

Q2. What is the Anthem Biosciences share price today?

Ans. Anthem Biosciences share price is trading around Rs 934 on the NSE, close to its 52-week high of Rs 973.50. The stock's 52-week low is Rs 579.15.

Q3. What is the Anthem Biosciences share price target?

Ans. Anthem Biosciences does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. Investors can check live research on the Univest Screener and consult a SEBI-registered adviser given the rich valuation involved.

Q4. What does Anthem Biosciences do?

Ans. Anthem Biosciences is a contract research, development and manufacturing organisation, serving pharmaceutical and biotechnology customers with services spanning small molecules, biologics and specialty ingredients.

Q5. What is Anthem Biosciences' market capitalisation and PE ratio?

Ans. Anthem Biosciences has a market capitalisation of approximately Rs 52,599 crore and trades at a price to earnings ratio of about 91.29 times, a very significant premium to the pharmaceutical services sector average PE of roughly 37.7 times.

Q6. Why did Anthem Biosciences' revenue decline in Q1 FY27?

Ans. Anthem Biosciences' Q1 FY27 revenue fell 21.3 percent year on year to Rs 443.11 crore, a softer quarter following a very strong full-year FY26 in which revenue grew 18.1 percent, likely reflecting typical CRDMO project timing variability.